|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.3300 - 0.3400|
|52 Week Range||0.0551 - 0.4399|
|Beta (5Y Monthly)||1.74|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for CANQF
TORONTO, ON / ACCESSWIRE / October 31, 2023 / NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® ...
CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), is pleased to announce it was awarded a European Cannabinoid Patent, a novel Botanical and Tetrahydrocannabinol ("THC") Formulation for the reduction of cannabis-induced negative neuropsychiatric side-effects.
CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical Awards by Global Health & Pharma, United Kingdom, a